Anzeige
Mehr »
Sonntag, 07.09.2025 - Börsentäglich über 12.000 News
Tokenisierung entfesselt: Republic führt die Ethereum-Revolution
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EEZB | ISIN: US72941H5090 | Ticker-Symbol: XMP0
NASDAQ
05.09.25 | 21:59
0,493 US-Dollar
+9,54 % +0,043
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
PLUS THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
PLUS THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur PLUS THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiPlus Therapeutics stock rating upgraded to Buy by D. Boral Capital3
26.08.Plus Therapeutics regains compliance with applicable Nasdaq listing criteria3
PLUS THERAPEUTICS Aktie jetzt für 0€ handeln
26.08.Plus Therapeutics regains Nasdaq compliance, extends bid price deadline3
26.08.Plus Therapeutics Inc.: Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria373HOUSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform...
► Artikel lesen
26.08.Plus Therapeutics erfüllt wieder NASDAQ-Anforderungen an Börsenwert und Eigenkapital5
26.08.PLUS THERAPEUTICS, INC. - 8-K, Current Report2
22.08.PLUS THERAPEUTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans2
18.08.Plus Therapeutics Inc.: Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ in Leptomeningeal Metastases137REYOBIQ produced a clinical benefit rate of over 75% in 3 clinically relevant outcome measures RNA sequencing and circulating tumor cell reduction consistent with tumor cell death No dose limiting...
► Artikel lesen
15.08.Plus Therapeutics Reports $3M in Stock Equity3
15.08.Plus Therapeutics meets Nasdaq equity requirement to maintain listing10
15.08.Plus Therapeutics GAAP EPS of -$0.01 beats by $0.07, revenue of $1.39M misses by $0.44M5
15.08.Plus Therapeutics Inc.: Plus Therapeutics Reports Stockholders' Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements114HOUSTON, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
► Artikel lesen
14.08.Plus Therapeutics Inc.: Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights228Announced CNSide® CSF assay platform launch timeline Initiated the REYOBIQ dose optimization trial for patients with leptomeningeal metastases HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Plus...
► Artikel lesen
14.08.PLUS THERAPEUTICS, INC. - 10-Q, Quarterly Report2
14.08.CNSide-Assay von Plus Therapeutics mit vielversprechenden Ergebnissen bei leptomeningealen Metastasen2
12.08.Plus Therapeutics files to sell 33M shares of common stock for holders4
12.08.PLUS THERAPEUTICS, INC. - 8-K, Current Report2
12.08.PLUS THERAPEUTICS, INC. - S-1, General form for registration of securities2
31.07.Plus Therapeutics: Diagnostikplattform CNSide startet im August 2025 in Texas16
31.07.Plus Therapeutics Inc.: Plus Therapeutics Provides US Launch Update for its CNSide Diagnostic182CNSide available for the state of Texas in August 2025 Initial commercial focus on NCI-Designated Cancer Centers and large private healthcare systems Company will expand testing services and broaden...
► Artikel lesen
Weiter >>
91 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2